

THE TRENDLINES GROUP LTD.

(Incorporated in Israel)

(Company Registration No. 513970947)

B. Braun Melsungen AG to Invest in Trendlines Medical Singapore Pte. Ltd.

The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries and associated companies, the “**Group**”) refers to the Company's announcement dated 18 July 2016 regarding the incorporation of a wholly-owned subsidiary, Trendlines Medical Singapore Pte. Ltd. (“**Trendlines Medical Singapore**”) in Singapore.

The Board wishes to announce that the Company has signed a non-binding Memorandum of Understanding (the “**MOU**”) with B. Braun Melsungen AG (“**B. Braun**”), a German medical and pharmaceutical device company, which sets forth the principal terms to be included in a definitive collaboration agreement to be entered into between the Company and B. Braun in connection with their investment in, and operation of, Trendlines Medical Singapore (the “**Definitive Agreement**”).

The MOU provides that, upon the execution of the Definitive Agreement, B. Braun shall subscribe for new ordinary shares in the capital of Trendlines Medical Singapore such that it will be a minority investor in Trendlines Medical Singapore.

In addition, the MOU provides that following such execution of the Definitive Agreement and subject to confirmation of funding from the Singapore Government, B. Braun and the Company (including third party investors, if any) will jointly invest in Trendlines Medical Singapore to support the development of its portfolio companies, and actively consider follow-on investment opportunities in these portfolio companies.

Subsequent to the investment by B. Braun (and third party investors, if any), the Company shall own a majority of the issued and outstanding share capital of Trendlines Medical Singapore.

B. Braun will appoint Ms. Anna Maria Braun, President of B. Braun Asia Pacific, as a member to the board of Trendlines Medical Singapore.

The Company and B. Braun shall endeavour to conclude the Definitive Agreement by no later than 30 September 2016. There is no certainty or assurance as at the date of this announcement that the Definitive Agreement will be entered as contemplated under the MOU and/or that the Singapore Government shall provide funding to Trendlines Medical Singapore.

Interest of Directors and Substantial Shareholders

None of the Company's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the MOU.

Further Announcement

The Company will make further announcement(s) if and when there are any material updates to the MOU including, *inter alia*, the execution of the Definitive Agreement between the Company and B. Braun and the material terms as contained in the Definitive Agreement.

**BY ORDER OF THE BOARD
THE TRENDLINES GROUP LTD.**

Yosef Ron,
Joint Company Secretary

8 September 2016

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.